Using Neuroimaging to Early Diagnose Alzheimer's Disease Through Hippocampal Atrophy Assessment

NCT06965816 | Completed DMC

• 1 other identifier: 0030_IMAGERIE
• Study Type: observational
• Target: 85
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to better understand Alzheimer's disease by looking at brain scans, specifically MRI images, to detect early signs of brain changes linked to the disease. Researchers are focusing on the hippocampus, a part of the brain that shrinks in people with Alzheimer's. The study will also explore other brain changes that often happen alongside hippocampal shrinkage. By analyzing these brain images, the study hopes to find ways to diagnose Alzheimer's earlier and more accurately using advanced imaging techniques.

Conditions

Alzheimer's Disease; Hippocampus; Brain Atrophy; Magnetic Resonance Imaging; Leukoaraiosis; Neurodegenerative Diseases; Cortical and Subcortical Atrophy

Outcome Measures

Primary Outcomes (1)

• Hippocampal Volume Measured by 3D MRI

  Objective volumetric measurement of the right and left hippocampus using 3D T1 Bravo MRI sequences, allowing quantification of hippocampal atrophy.

  Retrospective analysis between January 2018 and June 2022

Study Arms (2)

Alzheimer Group

Alzheimer's patients

Control Group

Unreached witnesses

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be selected from a retrospective cohort of patients who underwent brain MRI scans (3D T1 Bravo and Cube FLAIR sequences) between January 2018 and June 2022. The study population includes two groups: patients diagnosed with Alzheimer's disease based on clinical and biological assessments, and cognitively healthy individuals with no history of neurological or psychiatric disorders, serving as controls.

You may qualify if:

• Patients who underwent a brain MRI (3D T1 Bravo and Cube FLAIR sequences) between January 2018 and June 2022.
• Diagnosis of Alzheimer's disease (for the Alzheimer group).
• No neurological disease for control group participants.
• Complete clinical and biological assessments available.
• Quality imaging without motion artifacts.

You may not qualify if:

• Incomplete clinical or radiological data.
• Poor image quality (e.g., motion artifacts).
• Presence of other neurodegenerative or psychiatric disorders.

Sponsors & Collaborators

• Centre Hospitalier de Saint-Denis: lead

Study Sites (1)

France

Saint-Denis, France

Location

MeSH Terms

Conditions

Leukoaraiosis; Neurodegenerative Diseases

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Nervous System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2025
• First Posted: May 11, 2025
• Study Start: November 24, 2022
• Primary Completion: May 24, 2023
• Study Completion: May 24, 2023
• Last Updated: May 11, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)